Can Fite BiopharmaCANF +1.71%55 ROC (Joel Greenblatt) % is -11,887.06% as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $6.99 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,325 Biotechnology companies, Can Fite Biopharma ranks worse than 90.11% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Can Fite Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -11,887.06%.
The historical rank and industry rank for Can Fite Biopharma's ROC (Joel Greenblatt) % or its related term are showing as below:
CANF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14798.81 Med: -6961.5 Max: -516.89
Current: -9689.7
During the past 13 years, Can Fite Biopharma's highest ROC (Joel Greenblatt) % was -516.89%. The lowest was -14798.81%. And the median was -6961.50%.
CANF's ROC (Joel Greenblatt) % is ranked worse than 90.11% of 1325
companies
in the Biotechnology industry
Industry Median: -297.52
vs CANF: -9689.70
Can Fite Biopharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.50% per year.
Can Fite Biopharma (AMEX:CANF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Can Fite Biopharma ROC (Joel Greenblatt) % Related Terms
Can Fite Biopharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Can Fite Biopharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's ROC (Joel Greenblatt) % falls into.
Can Fite Biopharma ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -11,887.06% mean?
Can Fite Biopharma (CANF) has a ROC (Joel Greenblatt) % of -11,887.06% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #1194 out of 1325 companies in the Biotechnology industry, placing it in the top 90.1%.
Is Can Fite Biopharma's ROC (Joel Greenblatt) % too high?
Can Fite Biopharma's current ROC (Joel Greenblatt) % is -11,887.06%. Based on the distribution chart, Can Fite Biopharma ranks #1194 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #1194 out of 1325 companies for ROC (Joel Greenblatt) %. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current ROC (Joel Greenblatt) % is -11,887.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.99, compared to a current price of $2.97 — trading 57.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is -11,887.06%. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current ROC (Joel Greenblatt) % is -11,887.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.97 is trading 57.5% below its estimated GF Value™ of $6.99.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
ROC (Joel Greenblatt) %: -11,887.06%
GF Value™: $6.99 vs. price of $2.97 (57.5% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
